Analyst consensus for FY21

As at 20 December 2021

 

Low

High

Average (Mean)

Revenue (£m)

1,081.0

1,128.0

1,099.2

EBITDA (£m)

177.4

190.0

183.1

EBIT (£m)

82.2

95.0

89.0

PBT (£m)

-1.0

29.0

8.4

Net income (£m)

-20.4

7.0

-8.6

 

The figures shown above are on an adjusted, post IFRS 16 basis. They include estimates from five analysts who have updated their estimates following Spire Healthcare’s H1 FY21 results but exclude estimates from JP Morgan Cazenove who have not followed Company guidance.

 

View analyst consensus for FY22